Google X working on wearable that can measure pulse, heart rhythm, skin temperature, more; device meant to be prescribed to patients or used for clinical trials
Context & Ripple Effects
This is the origin point of a long arc: Google X's decision in 2015 to build a wearable meant to be prescribed to patients or run inside clinical trials, rather than sold as a consumer gadget. That medical-grade posture predates Google's later consumer-facing health push, when Pixel users got phone-camera pulse and breath-rate readings through Google Fit, and it foreshadows today's sensor-heavy features like the AI-driven insulin-resistance trend on the Pixel Watch 5 and Fitbit.
The prescription-and-trials framing matters because it puts Google on a regulated path alongside rivals chasing the same body-data prize: Amazon was separately reported to be building a voice-activated wellness wearable with emotion recognition, while Samsung has been exploring noninvasive glucose monitoring and blood pressure checking across its devices.
First-order effects
- A wearable cleared for prescriptions and clinical trials puts Google into the regulated medical-device channel, where buyers are clinicians and trial sponsors rather than retail shoppers.
Second-order effects
- Samsung's push into noninvasive glucose and blood-pressure sensing becomes a direct race for validated health metrics, pressuring both companies to prove clinical accuracy rather than just ship sensors.
Third-order effects
- If the pattern holds, wearables split into two tracks — consumer wellness devices and prescription-grade diagnostics — forcing every major player to decide whether its hardware must clear regulatory validation to stay competitive.
The trend: Big-tech wearables are converging from fitness trackers toward clinically validated diagnostic devices, with each sensor milestone pulling the category deeper into regulated medicine.